PaulAHamlinMD

PubMed

• A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
  Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew Matasar
  Leukemia & Lymphoma. 2024-12-01
• Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
  Jennifer K Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman
  Blood Cancer Journal. 2024-10-14
• Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
  Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, Michelle Okwali, Irem Isgor
  Haematologica. 2024-09-05

Abstracts/Posters

• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Aging and Hematologic Disorders: Exploring the Evidence 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018